Evolent Health, Inc Class A (EVH) Dividend History

Company News

• Dr. Abeer AbouYabis Scholarship for Future Doctors Inspires Aspiring Physicians to Tackle Healthcare Challenges

  The Dr. Abeer AbouYabis Scholarship for Future Doctors offers a $1,000 award to undergraduate students pursuing a medical career, encouraging them to envision their impact on the future of healthcare.

  GlobeNewswire Inc.
• Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say

  While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

  Zacks Investment Research
• Evolent Health (EVH) Q1 2024 Earnings Call Transcript

  EVH earnings call for the period ending March 31, 2024.

  The Motley Fool
• In-Depth Examination Of 6 Analyst Recommendations For Evolent Health

  Evolent Health (NYSE:EVH) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 3 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for Evolent Health, revealing an average target of $44.0, a high estimate of $52.00, and a low estimate of $38.00. A 3.3% drop is evident in the current average compared to the previous average price target of $45.50. Investigating Analyst Ratings: An Elaborate Study The perception of Evolent Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Daniel Grosslight Citigroup Announces Buy $40.00 - Richard Close Canaccord Genuity Lowers Buy $44.00 $45.00 Anne Samuel JP Morgan Lowers Overweight $52.00 $53.00 Jeff Jones Oppenheimer Announces Outperform $45.00 - Constantine Davides JMP Securities Raises Market Outperform $38.00 $37.00 Richard Close Canaccord Genuity Lowers Buy $45.00 $47.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Evolent ...Full story available on Benzinga.com

  Benzinga
• Here's how to decide whether the S&P 500 is now heading toward a correction

  Watch for these stock-market sell signals.

  MarketWatch

  Featured Companies: ADP CMS DKNG LDOS NKE PCAR